[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-504816-105":59,"doc-detail-504816-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","use-of-fibroscan-liver-elastography-in-the-rapid-diagnosis-and-monitoring-of-masld-treatment","Use of FibroScan Liver Elastography in the Rapid Diagnosis and Monitoring of MASLD Treatment","","Steatohepatitis associated with metabolic dysfunction is the most common chronic liver disease worldwide, often found incidentally and affecting about 30% of adults and about 10% of children. It drives major outcomes including hepatocellular carcinoma, cirrhosis, liver transplantation, and increased cardiovascular mortality, and the MASLD burden may double by 2030. Because the disease is frequently asymptomatic until advanced fibrosis or cirrhosis, non-invasive tools are needed to detect early steatosis and fibrosis and to monitor therapy and complications, including in paediatric patients. FibroScan liver elastography supports early detection, fibrosis assessment, treatment monitoring, and complication risk evaluation, with interpretation using specialized scales and guideline context.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/use-of-fibroscan-liver-elastography-in-the-rapid-diagnosis-and-monitoring-of-masld-treatment/504816/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/use-of-fibroscan-liver-elastography-in-the-rapid-diagnosis-and-monitoring-of-masld-treatment/504816.png","ImageObject",300,407,{"name":92,"@type":93},"jay","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-10-04",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is early detection of MASLD important?","Question",{"text":113,"@type":114},"MASLD is often asymptomatic for years, so diagnosis frequently occurs at advanced fibrosis or even cirrhosis and can follow cardiovascular events. Early, non-invasive detection is therefore needed.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does FibroScan liver elastography provide in MASLD care?",{"text":118,"@type":114},"FibroScan enables detection of hepatic steatosis at early stages and assessment of liver fibrosis. It also supports monitoring of treatment and estimation of possible complications.",{"name":120,"@type":111,"acceptedAnswer":121},"Which patient groups can benefit from this approach?",{"text":122,"@type":114},"The paper notes use in both adults and paediatric patients. It also highlights patients at risk such as obesity, pre-diabetes/type 2 diabetes, lipid disorders, or hypertension.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},504816,1791095114,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},3985747858866,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Annals of Case Reports  \nRajewski P, et al. Ann Case Rep: 9: 102129 [www.doi.org/10.29011/2574-7754.102129](www.doi.org/10.29011/2574-7754.102129)[ ](www.doi.org/10.29011/2574-7754.102129)[www.gavinpublishers.com](www.gavinpublishers.com)  \nCase Report  \nUse ofFibroscan Liver Elastography in the Rapid Diagnosis and Monitoring of MASLD Treatment  \nPaweł Rajewski1,2*, Jakub Cieściński3, Piotr Rajewski4  \n1Department of Internal and Infectious Diseases, Provincial Infectious Disease Hospital,85-030 Bydgoszcz, Poland 2Faculty of Health Sciences, University of Health Sciences in Bydgoszcz, 85-067 Bydgoszcz, Poland 3Department of Radiology, Provincial Infectious Disease Hospital,85-030 Bydgoszcz, Poland  \n4Department of Neurology, Collegium Medicum-Faculty of Medicine, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland  \n*Corresponding author: Paweł Rajewski, Department of Internal and Infectious Diseases, Provincial Infectious Disease Hospital,85-030 Bydgoszcz, Poland  \nCitation: Rajewski P, Ciescinski J, Rajewski P (2024) Use ofFibroscan Liver Elastography in the Rapid Diagnosis and Monitoring  \nof MASLD Treatment. Ann Case Report. 9: 2129. DOI:10.29011/2574-7754.102129  \nReceived: 14 December 2024, Accepted: 18 December 2024, Published: 20 December 2024  \nAbstract  \nSteatohepatitis associated with metabolic dysfunction is the most common chronic liver disease worldwide, usually detected incidentally and affecting nearly 30% of the adult population and nearly 10% of the child population. It is one of the leading causes of hepatocellular carcinoma, cirrhosis and liver transplantation in developed countries. It is also a significant factor in the development of cardiovascular disease, which is the leading cause of death in this group of patients. It is estimated that the number of patients with MASLD could double by 2030. Its long-standing asymptomatic nature means that at the time of diagnosis it is usually an advanced disease, with advanced liver fibrosis, and it is not uncommon for the diagnosis to be made atthe stage of cirrhosis or liver cancer or extrahepatic complications. Hence, non-invasive diagnostic methods are still being sought that will detect minimal steatosis ofthe hepatocytes, still in the subclinical phase in patients at risk-obesity, pre-diabetes or type 2 diabetes, lipid disorders or hypertension-faster than classic ultrasound. Such tools include FibroScan® liver elastography, which enables the detection of hepatic steatosis at its early stage and the assessment of liver fibrosis. It is also used to monitor treatment and estimate possible complications. It can also be used in the paediatric population. This paper discusses the feasibility ofFibro Scan as a diagnostic and treatment monitoring tool for MASLD, its advantages, potential disadvantages, how the test can be performed and interpreted, and the use of specialised scales based on the FibroScan® test and selected laboratory parameters to assess the development of liver complications, as well as its place in current guidelines of scientific societies.  \n1 Volume 09; Issue 06 Ann Case Rep, an open access journal  \nISSN: 2574-7754  \nKeywords: MASLD; Steatosis; Fibroscan; Liver Elastography; Cirrhosis.  \nIntroduction  \nMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, detected most often incidentally and affecting nearly 30% of the adult population and nearly 10% of the child population. It is one of the leading causes of hepatocellular carcinoma, cirrhosis and liver transplantation in the developed world-the first cause of cirrhosis and liver transplantation in women in the USA and the second in men. Also, in Europe, there is a noticeable increase in end-stage cirrhosis of MASLD aetiology and liver transplantation due to this cause. It is also an important factor in the development of cardiovascular disease. On the one hand, itisthe most common liver disease in the world, with a y","cbCaifJCGU5UENPn","https://ap.wps.com/l/cbCaifJCGU5UENPn","pdf",569509,"English","# Abstract\n# Keywords\n# Introduction\n# Methods and feasibility\n## How FibroScan is performed and interpreted\n# Clinical monitoring and interpretation\n## Specialized scales and laboratory parameters\n# Position in current guidelines","[{\"question\":\"Why is early detection of MASLD important?\",\"answer\":\"MASLD is often asymptomatic for years, so diagnosis frequently occurs at advanced fibrosis or even cirrhosis and can follow cardiovascular events. Early, non-invasive detection is therefore needed.\"},{\"question\":\"What does FibroScan liver elastography provide in MASLD care?\",\"answer\":\"FibroScan enables detection of hepatic steatosis at early stages and assessment of liver fibrosis. It also supports monitoring of treatment and estimation of possible complications.\"},{\"question\":\"Which patient groups can benefit from this approach?\",\"answer\":\"The paper notes use in both adults and paediatric patients. It also highlights patients at risk such as obesity, pre-diabetes/type 2 diabetes, lipid disorders, or hypertension.\"}]","Use of FibroScan Liver Elastography in the Rapid Diagnosis and Monitoring of MASLD Treatment | PDF",1791075998]